# Ensem Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ensem-therapeutics

- Industry: Biotechnology
- Headquarters: Medford, US
- Website: www.ensemtx.com
- Total disclosed funding: $67M
- Latest round: Series A (Apr 6, 2022)
- Investors on record: 5

## About

Based in Massachusetts, US, and founded in 2021, Ensem Therapeutics, Inc. operates as a biotechnology research company that develops drugs intended to discover, develop, and commercialize transformative oncology therapies. In April 2022, Ensem Therapeutics, Inc. raised USD 67 million in series A funding led by new investor GGV Capital, with participation from other new investors Pavilion Capital, Cenova Ventures, Mitsui & Co. Global Investment, Inc., and CBC Group. As of May 2022, the company is led by its CEO, Sean Cao.

Ensem Therapeutics, Inc. offers the Kinetic EnsembleTM platform that develops small molecule precision medicines for oncology, with expansion into genetic disorders and other disease areas. ENSEM integrates computational, artificial intelligence, and deep learning methodologies with experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design, with a focus on difficult-to-drug targets.

The company will use the series A funding to further advance its Kinetic Ensemble platform and boost its research and development pipeline.

## Funding rounds

- Series A, Apr 6, 2022, $67M — Granite Asia, Mitsui Global Investment, Cenova Ventures, Pavilion Capital, CBC Group

## Investors

- Granite Asia (https://capitalatlas.ai/funds/granite-asia) — Series A
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series A
- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series A
- Pavilion Capital — Series A
- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series A